nach oben

Erschienen in:

12.02.2016 | Original Article

Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery

verfasst von: Toshio Yamaguchi, Hideo Wada, Shinichi Miyazaki, Masahiro Hasegawa, Hiroki Wakabayashi, Kunihiro Asanuma, Naoki Fujimoto, Takeshi Matsumoto, Kohshi Ohishi, Akane Sakaguchi, Norikazu Yamada, Masaaki Ito, Yoshiki Yamashita, Naoyuki Katayama, Akihiro Sudo

Erschienen in: International Journal of Hematology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Venous thromboembolism (VTE) is a common complication in patients who have undergone major orthopedic surgery, but there are few predictors of VTE after major orthopedic surgery treated with an anticoagulant. We measured levels of fibrin-related markers (FRMs), such as d-dimer, soluble fibrin (SF), and fibrinogen and fibrin degradation products (FDPs) in 66 patients with acute-phase VTE, and 367 patients undergoing major orthopedic surgery. Plasma FDP, d-dimer, and SF levels were significantly higher in patients with acute VTE, but only FDP and d-dimer levels were significantly higher in subclinical VTE. Adequate cut-off levels of d-dimer were 2.2 μg/ml for diagnosing acute VTE and 1.5 μg/ml for diagnosing subclinical VTE. d-dimer of less than 1.9 or 0.7 μg/ml ruled out acute VTE or subclinical VTE. d-dimer of more than 1.3 μg/ml preoperatively showed a moderate risk for postoperative VTE. Measurement of FRMs is useful for evaluating the risk of subclinical or postoperative VTE in patients with major orthopedic surgery. In particular, FDP is the most valuable marker for diagnosing acute VTE, whereas d-dimer is the most valuable for diagnosing subclinical VTE or predicting VTE.

van der Hulle T, Dronkers CE, Huisman MV, Klok FA. Current standings in diagnostic management of acute venous thromboembolism: still rough around the edges. Blood Rev 2015 (in press).

Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M. VTE Impact Assessment Group in Europe (VITAE): venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemostasis. 2007;98:756–64.

Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370–2.CrossRefPubMedPubMedCentral

Geersing GJ, Zuithoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, Bates SM, Hoes AW, Kraaijenhagen RA, Oudega R, Schutgens RE, Stevens SM, Woller SC, Wells PS, Moons KG. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340.CrossRefPubMedPubMedCentral

Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N’gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378:41–48.CrossRefPubMed

Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Rutschmann O, Nonent M, Cornuz J, Thys F, Le Manach CP, Revel MP, Poletti PA, Meyer G, Mottier D, Perneger T, Bounameaux H, Perrier A. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet. 2008;371:1343–52.CrossRefPubMed

Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted d-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311:1117–24.CrossRefPubMed

Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta. 2014;436C:130–4.CrossRef

Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, Uchida A, Nobori T. Elevated levels of soluble fibrin or d-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;4:1253–8.CrossRefPubMed

10.

Nomura H, Wada H, Mizuno T, Katayama N, Abe Y, Noda M, Nakatani K, Matsumoto T, Ota S, Yamada N, Sudo A, Uchida A, Nobori T. Negative predictive value of d-dimer for diagnosis of venous thromboembolism. Int J Hematol. 2008;87:250–5.CrossRefPubMed

11.

Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227–35.CrossRefPubMed

12.

Geerts WH, Heit JA, Clagett P, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:S132–75.CrossRef

13.

Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus AS, Planès A, Passera R, Rouillon A. AIDA investigators.: deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3:2664–70.CrossRefPubMed

14.

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S–400S.CrossRefPubMed

15.

Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest. 1998;114:115S–8S.

16.

Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and 3 months after discharge. J Bone Joint Surg. 1999;81:932–40.CrossRefPubMed

17.

Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–61.CrossRefPubMed

18.

Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458–68.CrossRefPubMed

19.

Sudo A, Wada H, Nobori T, Yamada N, Ito M, Niimi R, et al. Cut-off values of d-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. Int J Hematol. 2009;89:572–6.CrossRefPubMed

20.

Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Ando H, Oshima S, et al. Monitoring for anti-Xa activity for prophylactic administration of fondaparinux in patients with artificial joint replacement. Int J Hematol. 2011;94(4):355–60.CrossRefPubMed

21.

Hasegawa M, Wada H, Wakabayashi H, Yoshida K, Miyamoto N, Asanuma K, et al. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. Clin Chim Acta. 2013;425:109–13.CrossRefPubMed

22.

Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Matsumoto T, Shimokariya Y, et al. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. Int J Hematol. 2012;95:160–6.CrossRefPubMed

23.

Yang Y, Zan P, Gong J, Cai M. d-dimer as a screening marker for venous thromboembolism After surgery among patients younger than 50 With lower limb fractures. Clin Appl Thromb Hemost. 2015 (in press).

24.

Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost. 2008;34:33–8.CrossRefPubMed

25.

Dempfle CE, Zips S, Ergül H, Heene DL. Fibrin assay comparative trial study group: the Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative d-dimer assays as basis for the development of d-dimer calibrators. FACT study group. Thromb Haemost. 2001;85:671–8.

26.

Aota T, Naitoh K, Wada H, Yamashita Y, Miyamoto N, Hasegawa M, Wakabayashi H, Yoshida K, Asanuma K, Matsumoto T, Ohishi K, Shimokariya Y, Yamada N, Nishikawa M, Katayama N, Uchida A, Sudo A. Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. Int J Hematol. 2014;100:450–6.CrossRefPubMed

Titel: Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery
verfasst von: Toshio Yamaguchi
Hideo Wada
Shinichi Miyazaki
Masahiro Hasegawa
Hiroki Wakabayashi
Kunihiro Asanuma
Naoki Fujimoto
Takeshi Matsumoto
Kohshi Ohishi
Akane Sakaguchi
Norikazu Yamada
Masaaki Ito
Yoshiki Yamashita
Naoyuki Katayama
Akihiro Sudo
Publikationsdatum: 12.02.2016
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 5/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-016-1954-x

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux

Expression of activated molecules on CD5+B lymphocytes in autoimmune hemolytic anemia

Comparison of myocardial T1 and T2 values in 3 T with T2* in 1.5 T in patients with iron overload and controls

Mechanisms of self-renewal in hematopoietic stem cells

The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells

“Imatinib-induced gastric antral vascular ectasia” in a reporting system of the Japanese Adverse Drug Event Report database

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie